Proof of Identity Key for S.104A Burden Shift: Delhi High Court Denies Access to Trade Secrets - 2025-07-23

Identity vs. Similarity: Delhi High Court Stalls Patent Discovery in High-Stakes Biologic Suit

The Delhi High Court, led by Justice Amit Bansal, has issued a significant ruling addressing the boundaries of discovery in patent litigation concerning biological drugs. In the suit filed by F-Hoffmann-La Roche AG against Zydus Lifesciences Limited, the court refused to grant access to the defendant's manufacturing process, emphasizing that the statutory burden-shifting mechanism under Section 104A of the Patents Act, 1970, requires clear proof of "identity" between products, not merely "similarity."

The Dispute: A Quest for Proprietary Process

The conflict stems from the plaintiffs' attempts to protect their patents covering Pertuzumab (marketed as Perjeta ). F-Hoffmann-La Roche (Roche) initiated a quia timet action, alleging that Zydus Lifesciences was poised to infringe upon its product patent (IN’632) and process patent (IN’646) by launching a "similar biologic" (biosimilar) drug.

Following a series of orders regarding interim relief, the plaintiffs sought the constitution of a "confidentiality club" to gain access to Zydus’s proprietary manufacturing process, which had been filed with the court in a sealed cover. Roche argued that since Zydus had utilized Perjeta as a reference drug for clinical trial approvals, the underlying manufacturing processes were likely identical, justifying a shift in the burden of proof under Section 104A of the Act.

Arguments on the Burden of Proof

Roche contended that under the amended provisions of the Code of Civil Procedure ( CPC ) and the Patents Act, it was imperative for the court to permit discovery to prevent the unauthorized use of their patented methods. They argued that in the realm of complex biologics, a "similar biologic" is effectively the result of nearly identical processes.

Conversely, Zydus Lifesciences maintained that the plaintiffs’ claim was a "fishing and roving inquiry." The defendant argued that Roche failed to meet the sine qua non condition of Section 104A: proving that the two end products are "identical." Zydus emphasized that "biosimilar" regulatory approval only denotes similarity in terms of safety, efficacy, and quality—not a manufacturing identity that would automatically infringe a process patent.

Legal Analysis: The "Identity" Threshold

Justice Bansal’s analysis focused on the legislative intent behind Section 104A. The court held that the burden-shifting provision, while designed to assist patentees in infringement cases where the defendant's process is hidden, is not an automatic right.

The court rejected the plaintiffs' attempt to rely on general discovery provisions under the Commercial Courts Act, holding that the Patents Act acts as a "specialized legislation" that overrides general procedural laws in cases of specific conflict. The court observed that merely naming a drug as a "similar biologic" for regulatory purposes does not equate to the legal threshold of "identical" products required to force the disclosure of a competitor's trade secrets.

Key Observations

The judgment clarifies that the term "identical" in patent law holds a high bar, distinct from the regulatory definitions of "biosimilars":

• "The products of the plaintiff and the defendant being identical is a sine qua non for the applicability of Section 104A of the Act. Mere similarity between the two products would not suffice."
• "The filing of the... application... by the defendant with the CDSCO by itself would not fulfil the requirement of Section 104A of the Act that the defendant’s product is identical to that of the plaintiffs."
• "The statutory use of the term ‘identical’ reflects the legislature’s conscious choice, and to read the same in a lower threshold would amount to judicial dilution of the requirement."

Final Decision and Implications

The court dismissed the application for the constitution of a confidentiality club, concluding that Roche failed to demonstrate the necessary threshold of identity to compel the disclosure of Zydus’s protected manufacturing processes.

For the pharmaceutical and biotech industries, this ruling serves as a cautionary tale for innovators: simply establishing regulatory similarity is insufficient to trigger procedural burdens in patent litigation. Future litigants will need to perform rigorous analytical characterization or reverse engineering to prove product identity before they can demand access to a competitor’s manufacturing secrets. The court’s decision underscores the judiciary's commitment to protecting trade secrets unless the statutory requirements for shifting the burden of proof are strictly satisfied.